Get Quartz in your inbox

Free daily briefing on global business news.

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial

Median survival reached 21.1 months with Imdelltra plus AstraZeneca's Imfinzi, versus 12.7 months for Imfinzi alone

NurPhoto / Getty Images

Amgen $AMGN announced interim Phase 3 results showing that its lung cancer drug Imdelltra, when paired with AstraZeneca $AZN's Imfinzi, cut patients' chances of dying by 58% in extensive-stage small cell disease of the lung. The hazard ratio was 0.42 at a median follow-up of close to 16 months, the company said.

Median overall survival was 21.1 months with the combination, compared with 12.7 months for Imfinzi alone. At one year, close to 80% of patients on the combination were alive, versus 53% on Imfinzi alone. The trial........

© Quartz